KIT-targeting antibody biotech Jasper Therapeutics is being renewed via a merger with Nasdaq-listed Kira Pharmaceuticals—but ...
Every year, the BIO International Convention brings together more than 20,000 leaders from across the global life sciences ...
Another biotech is squeezing into the crowded IPO waiting room just in time for the weekend. | Another biotech is squeezing ...
Jennifer Doudna, Ph.D., the Nobel Laureate best known for co-inventing the CRISPR system that has become the foundation for ...
Dimerix has bought an acute kidney injury (AKI) drug from Mission Therapeutics, paying (PDF) $5 million upfront and ...
GSK has ended development of camlipixant in chronic cough after delivering mixed phase 3 data, dealing a major blow to a potential blockbuster that analysts saw as the key 2026 catalyst for the ...
Eli Lilly has struck a deal to buy AtaiBeckley for $2.8 billion upfront, continuing its takeover spree to move into a ...
Biogen's leading tau-targeting candidate has slowed cognitive decline across a suite of different clinical assessments, ...
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...
Vogenx has joined the growing queue for the Nasdaq, as the metabolic biotech eyes an IPO to fund its SGLT1 inhibitor. | ...
Big Pharma-backed AdvanCell, flush with $315M series D, ready to put radiotherapy pedal to the metal
Less than a month after locking down a lease for a new U.S. headquarters, radiotherapy outfit AdvanCell is poised to push its ...
When Axiom Biosciences' stem cell therapy demonstrated a 0% mortality rate over two years in potentially fatal newborn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results